Tufts CSDD Impact Reports summarize current original research from Tufts CSDD and present it in a concise, easy-to-read format. This bi-monthly publication – the only one of its kind – presents data, analyses, and insights on critical drug development and regulatory issues.

Industry decision makers from pharma, biotech, CROs and niche provider companies use Tufts CSDD Impact Reports to keep informed – and to shape R&D, manufacturing, marketing, sales, and strategic planning decisions.

Timely topics recently covered in Tufts CSDD Impact Reports include:

• Cost to develop new biotech products
• Fastest drug developers enjoy revenue gains and cost savings
• Approval times for new drugs under PDUFA
• Recent developments in R&D analysis of EU biopharmaceutical reviews
• An analysis of FDA request for postmarketing studies
• The changing investigative site landscape
• FDA’s response to U.S. pediatric studies incentive

What professionals around the world say about Tufts CSDD Impact Reports

Subscribers also receive the Tufts CSDD Outlook Report, published in January, which highlights near-term pharmaceutical and biopharmaceutical drug development trends.

Subscription available in hard copy format or online in PDF format.

View Sample Issue

Annual Subscription for Six Bi-monthly Issues
$395 regular annual subscription rate ($445 outside the USA)
$195 special rate, limited to government, academic, and non-profit organizations ($245 outside the USA)

Click here to start your annual subscription.

Corporate Multi-Reader Subscriptions
Click here for more information about corporate multi-reader subscriptions.

Single Issue Rate: $100
Click here to order

To Renew
Click here to renew your subscription

To view samples, subscription, and single issue order forms, please download Adobe Acrobat Reader to your PC free of charge at: http://www.adobe.com/products/acrobat/readstep2.html.

Recent Tufts CSDD Impact Report single issues:

May/June 2008, vol.10, no.3
Drug plans non–compliant with Medicare
View summary    Purchase single issue

March/April 2008, vol.10, no.2
Number of mAbs entering clinical
study nearly tripled in last decade

View summary    Purchase single issue

January/February 2008, vol.10, no.1
Growing protocol design complexity
stresses investigators, volunteers
View summary    Purchase single issue

November/December 2007, vol.9, no.6
Notable gender & racial disparities
exist among clinical investigators
View summary    Purchase single issue

September/October 2007, vol.9, no.5
Despite more cancer drugs in R&D,
overall U.S. approval rate is 8%

View summary    Purchase single issue

July/August 2007, Vol. 9, No. 4
Follow–on drugs and indications play key role for World Health Organization
View summary    Purchase single issue

May/June 2007, Vol. 9, No. 3
Challenges loom for postmarketing
study commitments; benefits unclear
View summary    Purchase single issue

March/April 2007 Vol. 9, No. 2
Pediatric Study Costs Rose Substantially from 2000 as Complexity Grew
View summary    Purchase single issue

January/February 2007 Vol.9 No.1
EMEA meets performance goals, but lags U.S. FDA in drug approvals
View summary    Purchase single issue

2006 (click here to preview issues and summaries)

2005 (click here to preview issues and summaries)

2004 (click here to preview issues and summaries)

2003 (click here to preview issues and summaries)

2002 (click here to preview issues and summaries)

2001 (click here to preview issues and summaries)

2000 (click here to preview issues and summaries)

1999 (click here to preview issues and summaries)